Silodosin: An Update on Efficacy, Safety and Clinical Indications in Urology: Advances in Therapy

L Villa, P Capogrosso, U Capitanio, A Martini, A Briganti, A Salonia, F Montorsi

Research output: Contribution to journalArticlepeer-review


Introduction: Silodosin determines smooth muscle relaxation in bladder and prostate tissues, increases bladder blood flow in conditions of chronic bladder ischemia and regulates the activity of transcriptional factors responsible for stromal growth and prostate hyperplasia. Phase III trials have already demonstrated the efficacy and safety of silodosin in the treatment of patients bothered by lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). Objective: We aimed to describe the rationality for the use of silodosin and to summarize the current literature on the use of Silodosin for the treatment of LUTS. Methods: PubMed and Web of Science were queried with the terms: ‘silodosin’ in combination (AND) with the terms ‘lower urinary tract symptoms’, ‘LUTS’, ‘pathophysiology’, ‘symptoms’ OR ‘therapy’. Studies published in the last 10 years (2007–2017) in adults and core clinical journals in English were included. Results: Silodosin 8 mg once-daily was superior to placebo in improving IPSS total score, voiding subscore, storage subscore and QoL score, and at least as effective as tamsulosin 0.4 mg once-daily in all the efficacy analyses. In addition, studies assessing the effect on urodynamic parameters showed that silodosin determined a higher improvement in the bladder outlet obstruction index compared to other alpha1 adrenergic receptor antagonists. Concerning the safety profile, long-term data (after 9 months of treatment) confirmed the limited effect of silodosin on the cardiovascular and gastrointestinal systems. Although ejaculatory disorders represented the main complaint of patients taking silodosin, the discontinuation rate due to this condition remained low even in a long-term follow-up study (7.5%). Encouraging findings showed that silodosin may be administered as a medical expulsive therapy for promoting spontaneous stone passage of distal ureteral stones <10 mm, to relieve LUTS in patients who underwent prostate cancer brachytherapy and to increase the likelihood of successful trials without a catheter in patients experiencing acute urinary retention. Conclusion: Silodosin is one of the drugs approved for the treatment of BPH, being highly effective in improving not only LUTS but also urodynamic parameter impairments secondary to BPH. Moreover, it has shown efficacy as medical expulsive therapy for distal ureteral stones in previous prospective randomized trials. Funding: Sponsorship for this study and article processing charges were funded by Recordati. © 2018, Springer Healthcare Ltd., part of Springer Nature.
Original languageEnglish
Pages (from-to)1-18
Number of pages18
JournalAdvances in Therapy
Issue number1
Publication statusPublished - 2019


Dive into the research topics of 'Silodosin: An Update on Efficacy, Safety and Clinical Indications in Urology: Advances in Therapy'. Together they form a unique fingerprint.

Cite this